Skip to main content
Premium Trial:

Request an Annual Quote

Phylonix Snags $1.25M Grant for Zebrafish Drug Interaction Test

NEW YORK (GenomeWeb News) — Phylonix Pharmaceuticals has received a Small Business Innovation Research Grant from the National Institute of General Medical Sciences that it will use to develop its drug-interaction testing technology.
The Cambridge, Mass.-based contract research organization will use the $1.25 million grant to develop in vivo zebrafish assays that will assess drug effects using cytochrome P450 profiling. The company markets and is developing screens to identify drug candidates for cancers, central nervous system disorders, cardiovascular diseases, apoptosis, and organ toxicity.
Because of their genetic and physiological similarity to humans, zebrafish have been shown to be an efficient, predictive animal model for assessing drug metabolism and drug safety, Phylonix said.
"A rapid and robust whole zebrafish CYP assay, amenable to automation in multiwell plate formats, will accelerate drug metabolism and safety profiling and reduce the possibility of costly late-stage drug development failures or product market withdrawal after commercialization," Phylonix CEO Patricia McGrath said in statement.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.